Get the Stockscreener App
8.22
41.66%
-5.87
Pre-market:
8.56
0.34
+4.14%
Seres Therapeutics Inc stock is traded at $8.22, with a volume of 688.24K.
It is down -41.66% in the last 24 hours and down -48.11% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$14.09
Open:
$10.04
24h Volume:
688.24K
Relative Volume:
4.69
Market Cap:
$74.36M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-411.00
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
-38.66%
1M Performance:
-48.11%
6M Performance:
-46.76%
1Y Performance:
-49.75%
1-Day Range:
$8.0033
$10.96
1-Week Range:
$8.0033
$14.69
52-Week Range:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
8.22 | 127.47M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Pauses SER-155 Phase 2 Study, Cuts Costs - marketscreener.com
Seres provides program and corporate updates and prioritizes emerging programs in inflammatory & immune diseases - marketscreener.com
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics pauses work on lead drug program amid cash crunch - The Business Journals
Seres pauses investments for lead program (MCRB:NASDAQ) - Seeking Alpha
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash - Bitget
Seres Shares Down After Co Pauses Drug Development, Lays Off Workers - marketscreener.com
Seres stock falls after pausing Phase 2 study and cutting workforce by 30% By Investing.com - Investing.com Nigeria
Seres stock falls after pausing Phase 2 study and cutting workforce by 30% - Investing.com UK
Biopharmaceutical company Seres Therapeutics, Inc. recently announced the implementation of a series of strategic adjustments aimed at extending its corporate operating cycle. - Bitget
Seres to lay off staff, pause top program in latest reboot - Yahoo Finance
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell? - Defense World
Seres Therapeutics announces leadership transition - MSN
Trading Recap: Should I invest in Seres Therapeutics Inc before earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' - Seeking Alpha
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageHere's What Happened - MarketBeat
Microbiome Therapeutics for Patients and PhysiciansMedical / Health Care - Environmental XPRT
Dividend Watch: How does Seres Therapeutics Inc perform in inflationary periods2025 Performance Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Investment Review: How does Seres Therapeutics Inc perform in inflationary periods2025 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average – Should You Sell? - Defense World
Institution Moves: How does ALEX perform in inflationary periodsJuly 2025 Selloffs & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Analyst Calls: Can Seres Therapeutics Inc weather a recessionMarket Growth Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell? - Defense World
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aug Retail: Is Pro Dex Inc benefiting from interest rate changesWeekly Market Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Chart Watch: Can Seres Therapeutics Inc weather a recessionEarnings Risk Summary & High Accuracy Trade Alerts - baoquankhu1.vn
Whats next for Seres Therapeutics Inc stockMarket Sentiment Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Momentum: Will Seres Therapeutics Inc. stock deliver better than expected guidance2025 Top Gainers & Capital Efficient Trading Techniques - Bộ Nội Vụ
Will Seres Therapeutics Inc. stock deliver better than expected guidanceWeekly Market Summary & Free High Accuracy Swing Entry Alerts - Улправда
Seres Therapeutics, Inc.Common Stock (NQ: MCRB - FinancialContent
Published on: 2026-01-13 00:08:06 - ulpravda.ru
Seres Therapeutics publishes new insights on VOWST mechanism By Investing.com - Investing.com Nigeria
Why Seres Therapeutics Inc. stock is in analyst buy zone2026 world cup usa national team final playmakers low block defense expert forecast expert opinion - Улправда
Seres Therapeutics expands board, appoints new director - MSN
Seres Therapeutics publishes new insights on VOWST mechanism - Investing.com
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewswire
Seres Therapeutics Q1 2025 Earnings Preview - MSN
Why Seres Therapeutics Inc. stock is rated strong buyInterest Rate Changes & Minimal Risk High Reward - bollywoodhelpline.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageHere's Why - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Here’s Why - Defense World
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
How Seres Therapeutics Inc. stock responds to policy changesGlobal Markets & Verified Entry Point Detection - Улправда
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era - FinancialContent
Can Seres Therapeutics Inc. (1S90) stock stage a strong rebound this quarterMarket Volume Report & Fast Gain Swing Alerts - DonanımHaber
Why analysts remain bullish on Seres Therapeutics Inc. stockRate Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is Seres Therapeutics Inc. stock affected by interest rate hikesCPI Data & Weekly Return Optimization Alerts - Улправда
Will Seres Therapeutics Inc. stock gain from government policiesJuly 2025 Market Mood & Weekly Top Stock Performers List - Улправда
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):